FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1903310257> ?p ?o ?g. }

• W1903310257 endingPage "6781" @default.
• W1903310257 startingPage "6773" @default.
• W1903310257 abstract "ABSTRACT This study addresses the role of Ebola virus (EBOV) specific infectivity in virulence. Filoviruses are highly lethal, enveloped, single-stranded negative-sense RNA viruses that can cause hemorrhagic fever. No approved vaccines or therapies exist for filovirus infections, and infectious virus must be handled in maximum containment. Efficacy testing of countermeasures, in addition to investigations of pathogenicity and immune response, often requires a well-characterized animal model. For EBOV, an obstacle in performing accurate disease modeling is a poor understanding of what constitutes an infectious dose in animal models. One well-recognized consequence of viral passage in cell culture is a change in specific infectivity, often measured as a particle-to-PFU ratio. Here, we report that serial passages of EBOV in cell culture resulted in a decrease in particle-to-PFU ratio. Notably, this correlated with decreased potency in a lethal cynomolgus macaque ( Macaca fascicularis ) model of infection; animals were infected with the same viral dose as determined by plaque assay, but animals that received more virus particles exhibited increased disease. This suggests that some particles are unable to form a plaque in a cell culture assay but are able to result in lethal disease in vivo . These results have a significant impact on how future studies are designed to model EBOV disease and test countermeasures. IMPORTANCE Ebola virus (EBOV) can cause severe hemorrhagic disease with a high case-fatality rate, and there are no approved vaccines or therapies. Specific infectivity can be considered the total number of viral particles per PFU, and its impact on disease is poorly understood. In stocks of most mammalian viruses, there are particles that are unable to complete an infectious cycle or unable to cause cell pathology in cultured cells. We asked if these particles cause disease in nonhuman primates by infecting monkeys with equal infectious doses of genetically identical stocks possessing either high or low specific infectivities. Interestingly, some particles that did not yield plaques in cell culture assays were able to result in lethal disease in vivo . Furthermore, the number of PFU needed to induce lethal disease in animals was very low. Our results have a significant impact on how future studies are designed to model EBOV disease and test countermeasures." @default.
• W1903310257 created "2016-06-24" @default.
• W1903310257 creator A5021969142 @default.
• W1903310257 creator A5022531953 @default.
• W1903310257 creator A5031055552 @default.
• W1903310257 creator A5031670950 @default.
• W1903310257 creator A5032930486 @default.
• W1903310257 creator A5041514461 @default.
• W1903310257 creator A5044285378 @default.
• W1903310257 creator A5046730948 @default.
• W1903310257 creator A5068939333 @default.
• W1903310257 creator A5079119151 @default.
• W1903310257 creator A5080679364 @default.
• W1903310257 creator A5083456420 @default.
• W1903310257 date "2015-07-01" @default.
• W1903310257 modified "2023-10-14" @default.
• W1903310257 title "Particle-to-PFU Ratio of Ebola Virus Influences Disease Course and Survival in Cynomolgus Macaques" @default.
• W1903310257 cites W167493483 @default.
• W1903310257 cites W1930242224 @default.
• W1903310257 cites W1972992267 @default.
• W1903310257 cites W1983134928 @default.
• W1903310257 cites W2000241775 @default.
• W1903310257 cites W2006204678 @default.
• W1903310257 cites W2010793106 @default.
• W1903310257 cites W2011591223 @default.
• W1903310257 cites W2014282186 @default.
• W1903310257 cites W2018581823 @default.
• W1903310257 cites W2022291864 @default.
• W1903310257 cites W2028191350 @default.
• W1903310257 cites W2029654125 @default.
• W1903310257 cites W2068672631 @default.
• W1903310257 cites W2077787787 @default.
• W1903310257 cites W2079928928 @default.
• W1903310257 cites W2081877186 @default.
• W1903310257 cites W2089872165 @default.
• W1903310257 cites W2099471944 @default.
• W1903310257 cites W2107341969 @default.
• W1903310257 cites W2113830822 @default.
• W1903310257 cites W2115102869 @default.
• W1903310257 cites W2116193045 @default.
• W1903310257 cites W2121706409 @default.
• W1903310257 cites W2138324531 @default.
• W1903310257 cites W2141935958 @default.
• W1903310257 cites W2144316492 @default.
• W1903310257 cites W2145933466 @default.
• W1903310257 cites W2161081629 @default.
• W1903310257 cites W2161501499 @default.
• W1903310257 cites W4210710163 @default.
• W1903310257 cites W4298221064 @default.
• W1903310257 cites W4320995993 @default.
• W1903310257 doi "https://doi.org/10.1128/jvi.00649-15" @default.
• W1903310257 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4468478" @default.
• W1903310257 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25903348" @default.
• W1903310257 hasPublicationYear "2015" @default.
• W1903310257 type Work @default.
• W1903310257 sameAs 1903310257 @default.
• W1903310257 citedByCount "58" @default.
• W1903310257 countsByYear W19033102572015 @default.
• W1903310257 countsByYear W19033102572016 @default.
• W1903310257 countsByYear W19033102572017 @default.
• W1903310257 countsByYear W19033102572018 @default.
• W1903310257 countsByYear W19033102572019 @default.
• W1903310257 countsByYear W19033102572020 @default.
• W1903310257 countsByYear W19033102572021 @default.
• W1903310257 countsByYear W19033102572022 @default.
• W1903310257 countsByYear W19033102572023 @default.
• W1903310257 crossrefType "journal-article" @default.
• W1903310257 hasAuthorship W1903310257A5021969142 @default.
• W1903310257 hasAuthorship W1903310257A5022531953 @default.
• W1903310257 hasAuthorship W1903310257A5031055552 @default.
• W1903310257 hasAuthorship W1903310257A5031670950 @default.
• W1903310257 hasAuthorship W1903310257A5032930486 @default.
• W1903310257 hasAuthorship W1903310257A5041514461 @default.
• W1903310257 hasAuthorship W1903310257A5044285378 @default.
• W1903310257 hasAuthorship W1903310257A5046730948 @default.
• W1903310257 hasAuthorship W1903310257A5068939333 @default.
• W1903310257 hasAuthorship W1903310257A5079119151 @default.
• W1903310257 hasAuthorship W1903310257A5080679364 @default.
• W1903310257 hasAuthorship W1903310257A5083456420 @default.
• W1903310257 hasBestOaLocation W19033102571 @default.
• W1903310257 hasConcept C104317684 @default.
• W1903310257 hasConcept C106358424 @default.
• W1903310257 hasConcept C134040284 @default.
• W1903310257 hasConcept C142724271 @default.
• W1903310257 hasConcept C159047783 @default.
• W1903310257 hasConcept C203014093 @default.
• W1903310257 hasConcept C2522874641 @default.
• W1903310257 hasConcept C2777469322 @default.
• W1903310257 hasConcept C2779134260 @default.
• W1903310257 hasConcept C524204448 @default.
• W1903310257 hasConcept C55493867 @default.
• W1903310257 hasConcept C60987743 @default.
• W1903310257 hasConcept C70913881 @default.
• W1903310257 hasConcept C71924100 @default.
• W1903310257 hasConcept C86803240 @default.
• W1903310257 hasConceptScore W1903310257C104317684 @default.
• W1903310257 hasConceptScore W1903310257C106358424 @default.
• W1903310257 hasConceptScore W1903310257C134040284 @default.

• next